A New Paradigm in Cardiovascular Disease Management Through Innate Immunity Control

The FRESH-MI clinical study, led by Radboud University Medical Center in the Netherlands, aims to evaluate the physiological effects of a plant-based diet on the innate immune system in patients with acute myocardial infarction (AMI). While conventional cardiovascular disease management primarily relies on pharmacological interventions such as statins and ezetimibe to treat hyperlipidemia, this study seeks to determine whether non-pharmacological interventions, specifically dietary changes, can directly modulate the inflammatory response of immune cells. Chronic residual inflammation following myocardial infarction is a key factor that increases the risk of recurrence; therefore, demonstrating the potential for immune modulation through dietary changes could significantly alter patient management protocols.

Ensuring Data Objectivity Through a Crossover Design Clinical Trial

This research is meticulously designed as a randomized, open-label, blinded-endpoint (PROBE) proof-of-concept (POC) clinical trial. Patients will follow a plant-based diet for five weeks, followed by a six-week washout period, and then return to their usual diet for another five weeks, following a crossover design. The researchers will collect blood samples at each stage and quantitatively track changes in the levels of inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), produced by monocytes under lipopolysaccharide (LPS) stimulation. In particular, data on infarct size, measured by cardiovascular magnetic resonance (CMR), will be used to correct for cytokine response analysis, thereby thoroughly controlling for extraneous variables.

Overcoming the Limitations of Drug Therapy and Exploring Synergistic Effects

The global cardiovascular disease treatment market, currently valued at $241.2 billion, is dominated by traditional drugs such as Lipitor and PCSK9 inhibitors such as Repatha. However, the industry is increasingly focusing on the risk of residual inflammatory response, even with drug administration, and is trending toward the addition of anti-inflammatory drugs such as colchicine (Lodoco). The FRESH-MI study can provide clinical evidence for a low-cost, high-efficiency dietary intervention that can replace or supplement these expensive anti-inflammatory drug therapies. This has the potential to become an innovative adjunctive therapy that reduces patient concerns about drug side effects and alleviates the financial burden on healthcare systems.

Scalability to Digital Healthcare and Medical Food Markets

The results of this study will not only be of academic interest but will also serve as a catalyst for the growth of the medical food industry and personalized digital healthcare platforms. Healthy controls (e.g., the patient's spouse) will also participate in the clinical trial to evaluate dietary adherence and feasibility, making it possible to immediately apply the findings to the design of behavioral intervention programs. If a plant-based diet is proven to positively modulate trained immunity, the epigenetic reprogramming of innate immune cells, the cardiac rehabilitation program market and related healthcare subscription models will evolve to a new level based on scientific data.